Anjali Jain

E. Savarino, E. Giannini, S. Tolone, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.

J. Barkin, Katherine A. Drake, M. Abreu, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay

D. Rubin, Anjali Jain, S. Naik, 2017, Current medical research and opinion.

Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.

C. Siegel, E. Scherl, D. Lukin, 2020, Inflammatory bowel diseases.

Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases

M. Dubinsky, P. Beniwal-Patel, R. Ungaro, 2019, Digestive Diseases and Sciences.

Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.

M. Dubinsky, P. Beniwal-Patel, D. Stein, 2019, Journal of Crohn's & colitis.

Non-invasive Serological Monitoring for Crohn’s Disease Postoperative Recurrence

M. Kamm, P. De Cruz, A. Hamilton, 2022, Journal of Crohn's & colitis.

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2015, Oncotarget.

The current and projected economic burden of Parkinson's disease in the United States

T. Dall, M. Storm, Timothy M. Dall, 2013, Movement disorders : official journal of the Movement Disorder Society.

Analysis & commentary: The US Preventive Services Task Force should consider a broader evidence base in updating its diabetes screening guidelines.

C. Goodman, Yiduo Zhang, J. Wolcott, 2012, Health affairs.

Preoperative Serum Vedolizumab Levels Do Not Impact Postoperative Outcomes in Inflammatory Bowel Disease

S. Targan, D. McGovern, N. Lopez, 2021, Diseases of the colon and rectum.

Patients with Low Drug Levels or Antibodies to a Prior Anti-TNF Are More Likely to Develop Antibodies to a Subsequent Anti-TNF.

M. Silverberg, F. Rieder, S. Flier, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease

A. Cohen, A. Bitton, E. Seidman, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Tu1311 Validation of a Homogenous Mobility Shift Assay (HMSA) for the Measurement of Ustekinumab (UTK) and Antibodies-to-Ustekinumab (ATU) in Inflammatory Bowel Disease (IBD) Patient Serum

S. Westin, Sharat Singh, Anjali Jain, 2015 .

Cost of illness for neuromuscular diseases in the United States

P. Hogan, Yiduo Zhang, Wenya Yang, 2014, Muscle & nerve.

DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN'S DISEASE BASED ON SERUM LEVELS OF PROTEINS.

M. Silverberg, S. Vermeire, E. Savarino, 2019, Gastroenterology.

A model for self-management of chronic filarial lymphoedema with acute dermato-lymphangio-adenitis

J. Shetye, Anjali Jain, Ekta Patil, 2021, BMJ Case Reports.

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index

M. Silverberg, D. Wolf, D. Hudesman, 2021, Crohn's & Colitis 360.

Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations.

M. Dubinsky, J. Colombel, T. Dervieux, 2021, Inflammatory bowel diseases.

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases

M. Regueiro, P. Deepak, M. Osterman, 2020, Digestive Diseases and Sciences.

S0814 Endoscopic Healing Index Is Inversely Correlated With Serum Infliximab Concentrations in Crohn’s Disease Patients: A Retrospective Analysis of the TAILORIX Clinical Trial Cohort

S. Vermeire, G. D'Haens, T. Dervieux, 2020 .

Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn's Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab

D. Stein, A. Yarur, Anjali Jain, 2017 .

Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.

Siddharth Singh, M. Valasek, W. Sandborn, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The Effect of Ethnicity in the Rate of Beta Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis.

Kathleen C. Fraser, Mark S. Anderson, Renee A. Davis, 2020, The Journal of clinical endocrinology and metabolism.

P394 Preoperative serum vedolizumab levels do not predict postoperative outcomes in inflammatory bowel disease (IBD)

S. Targan, D. McGovern, N. Lopez, 2018 .

S811 Evaluation of Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: Post Hoc Analysis From the Phase 3 True North Study

A. Ananthakrishnan, P. Irving, I. Blumenstein, 2022, American Journal of Gastroenterology.

Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.

Xiao-Jun Li, L. Mimms, R. Loomba, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Cost of illness for neuromuscular diseases in the U.S

P. Hogan, Yiduo Zhang, Wenya Yang, 2014 .

P533 Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response

A. Bitton, E. Seidman, C. Lemieux, 2019, Journal of Crohn's & Colitis.

A Novel Serum Test to Describe the Mucosal Healing State by Disease Location in Crohnʼs Disease Patients: 599

S. Vermeire, M. Hale, D. Laharie, 2017 .

Development and Validation of a Multi-marker Serum Test for the Assessment of Mucosal Healing in Crohnʼs Disease Patients: 600

M. Silverberg, S. Vermeire, E. Savarino, 2017 .

A Non-Invasive Serological Test to Assess the Efficacy of Biologic and Non-Biologic Therapies on the Mucosal Health of Patients With Crohnʼs Disease: 727

S. Vermeire, E. Savarino, W. Sandborn, 2017 .

Tu1725 EFFECTS OF OZANIMOD ON HISTOLOGIC REMISSION AND MUCOSAL HEALING OVER 3 YEARS OF CONTINUOUS TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

R. Panaccione, S. Danese, M. Abreu, 2023, Gastroenterology.

Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension

S. Vermeire, R. Panaccione, S. Danese, 2023, Journal of Crohn's & colitis.

Analysis & commentary: The US Preventive Services Task Force should consider a broader evidence base in updating its diabetes screening guidelines.

C. Goodman, Yiduo Zhang, J. Wolcott, 2012, Health affairs.

Use of the Endoscopic Healing Index for Monitoring of Disease Activity in Patients With Crohn’s Disease in the COVID Era

S. Hanauer, M. Abreu, T. Dervieux, 2020, Crohn's & colitis 360.